MARKET

DFTX

DFTX

Definium Therapeutics
NASDAQ
47.07
-1.38
-2.85%
After Hours: 46.45 -0.62 -1.31% 19:49 07/10 EDT
OPEN
47.73
PREV CLOSE
48.45
HIGH
48.39
LOW
44.52
VOLUME
2.56M
TURNOVER
--
52 WEEK HIGH
49.20
52 WEEK LOW
6.95
MARKET CAP
6.25B
P/E (TTM)
-18.8877
1D
5D
1M
3M
1Y
5Y
1D
Psychedelic: Compass Pathways reports six-month data for psilocybin drug
TipRanks · 2d ago
Definium Therapeutics Is Maintained at Buy by Stifel
Dow Jones · 3d ago
Stifel Maintains Buy on Definium Therapeutics, Raises Price Target to $60
Benzinga · 3d ago
Definium Therapeutics price target raised to $60 from $30 at Stifel
TipRanks · 3d ago
DEFINIUM THERAPEUTICS INC <DFTX.O>: STIFEL RAISES TARGET PRICE TO $60 FROM $30
Reuters · 3d ago
Definium Therapeutics (DFTX) Following Russell Index Removal And The Fair Value Debate
Simply Wall St · 3d ago
Definium Therapeutics issues inducement stock options for 169,740 shares to new hires
PUBT · 4d ago
Weekly Report: what happened at DFTX last week (0629-0703)?
Weekly Report · 5d ago
More
About DFTX
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Webull offers Definium Therapeutics Inc stock information, including NASDAQ: DFTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DFTX stock methods without spending real money on the virtual paper trading platform.